ArticleWorld journal of gastroenterology2004
Effects of daidzein on estrogen-receptor-positive and negative pancreatic cancer cells in vitro.
Article in World journal of gastroenterology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 51 citations in OpenAlex.
- Potential of Dietary Agent Daidzein in Cancer Prevention and Treatment: Opportunities and Challenges.Cancers · 2026Review
- Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.British journal of cancer · 2025Article
- Gut Microbiota-Assisted Synthesis, Cellular Interactions and Synergistic Perspectives of Equol as a Potent Anticancer Isoflavone.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Methionine γ-Lyase-Daidzein in Combination with S-Propyl-L-cysteine Sulfoxide as a Targeted Prodrug Enzyme System for Malignant Solid Tumor Xenografts.International journal of molecular sciences · 2022Article
- Chrysin-Induced G Protein-Coupled Estrogen Receptor Activation Suppresses Pancreatic Cancer.International journal of molecular sciences · 2022Article
- Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity.RSC medicinal chemistry · 2022Review
- Article
- Phytoestrogen blood levels and adverse outcomes in women with suspected ischemic heart disease.European journal of clinical nutrition · 2021Article
- Daidzein Induces Intrinsic Pathway of Apoptosis along with ER α/β Ratio Alteration and ROS Production.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Modifications on the Tetrahydroquinoline Scaffold Targeting a Phenylalanine Cluster on GPER as Antiproliferative Compounds against Renal, Liver and Pancreatic Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Anti-tumor effect of aloe-emodin on cervical cancer cells was associated with human papillomavirus E6/E7 and glucose metabolism.OncoTargets and therapy · 2019Article
- Ameliorative Effect of Daidzein on Cisplatin-Induced Nephrotoxicity in Mice via Modulation of Inflammation, Oxidative Stress, and Cell Death.Oxidative medicine and cellular longevity · 2017Article
- The epigenome as a potential mediator of cancer and disease prevention in prenatal development.Nutrition reviews · 2013Review
- Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.British journal of pharmacology · 2012Review
- Daidzein induces neuritogenesis in DRG neuronal cultures.Journal of biomedical science · 2012Article
- The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor α protein.British journal of pharmacology · 2011Article
- Potent genistein derivatives as inhibitors of estrogen receptor alpha-positive breast cancer.Cancer biology & therapy · 2011Article
- Effect of daidzein on cisplatin-induced hematotoxicity and hepatotoxicity in experimental rats.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo study the effects of daidzein on human pancreatic cancer cells in vitro.
methodsHuman estrogen-receptor (ER)-positive pancreatic cancer cells MiaPaCa-2 and ER-negative pancreatic cancer cells PANC-1 were treated by 0.1 micromol/L, 1 micromol/L, 10 microL, 25 microL, 50 microL, 75 microL and 100 microL of daidzein, respectively. Its antiproliferative effect was studied by MTT assay.
resultsDaidzein inhibited the growth of MiaPaCa-2 and PANC-1 cells at the concentrations from 0.1 microL to 100 microL. A dose- and time-dependent manner was found. The IC(50) of daidzein on MiaPaCa-2 and PANC-1 cells was 45 microL and 75 micro, respectively. After MiaPaCa-2 cells were treated by daidzein for 3 d and at the concentrations more than IC(50), the inhibitory manner was identical and the inhibition appeared a saturation phenomenon, but the inhibitory manner of daidzein on PANC-1 cells was different from that of MiaPaCa-2 cells.
conclusionDaidzein has antiproliferative effects on human estrogen-receptor-positive and negative pancreatic cancer cells, but their mechanisms may be different.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.